Should I buy Bristol-Myers Squibb Company (BMY)?

What Strong Buy means for BMY today

A Strong Buy rating is the output of the composite fair-value band ($68.8–$101) compared with the live price ($56.2), a 6.5/10 moat score, and a 80/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

BMY is rated Strong Buy at $56.16 versus the reconciled fair value midpoint of $84.55, implying +50.55% upside/downside. Confidence is separately disclosed at 80/100. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 10%): target $100.89, return +79.6%. Base case (probability 40%): target $84.55, return +50.6%. Bear case (probability 50%): target $68.85, return +22.6%.

Probability weights are not symmetric. Bristol-Myers Squibb Company is a turnaround stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for Bristol-Myers Squibb Company are: Pipeline Replacement Failure; Severe IRA Margin Compression; Dilutive Desperation M&A. The single biggest risk is Pipeline Replacement Failure: New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.

The biggest opportunity is Bull: New product launches scale much faster than anticipated, completely offsetting LOE impacts. The company returns to mid-single-digit revenue growth. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Strong Buy rating with 80/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/bmy/analysis.

Frequently asked questions